[HTML][HTML] Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease
J Marsal, M Barreiro-de Acosta, I Blumenstein… - Frontiers in …, 2022 - frontiersin.org
… A retrospective, observational cohort study of 722 patients … ustekinumab, while an extensive
literature review of clinical … While hepatitis B vaccination is usually performed in newborns, …
literature review of clinical … While hepatitis B vaccination is usually performed in newborns, …
Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study
…, M Vidon, A Benezech, C Rabaud, C Baumann… - Clinical …, 2022 - Elsevier
… hepatitis B or C, date of highly active antiretroviral therapy (… and biologics (anti-tumor necrosis
factor [TNF], ustekinumab, or … this is the first multicenter study addressing the impact of HIV …
factor [TNF], ustekinumab, or … this is the first multicenter study addressing the impact of HIV …
[HTML][HTML] Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in northern Italy
L Mastorino, P Dapavo, M Trunfio… - Acta dermato …, 2022 - ncbi.nlm.nih.gov
… anti-tumour necrosis factor-α. Overall, 10.5% of this group of … and clinical evidence on the
role of biologics and their safety … In our series, 3 patients were treated with ustekinumab for a …
role of biologics and their safety … In our series, 3 patients were treated with ustekinumab for a …
Effectiveness and safety of Ustekinumab for moderate to severely active Crohn's disease: results from an early access program in Brazil
… with Crohn’s disease (CD) refractory to anti-tumor necrosis factor… study retrospectively
evaluated 1,113 CD patients and … virus antibody, hepatitis B surface antigen, hepatitis C antibody, …
evaluated 1,113 CD patients and … virus antibody, hepatitis B surface antigen, hepatitis C antibody, …
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
…, A Gambardella, C Guarneri, C Foti… - Journal of …, 2022 - Taylor & Francis
… by retrospective chart review on patients with moderate-to-… for psoriasis, especially anti-tumor
necrosis factor (TNF)-α … clinical trials and post-marketing safety surveillance in 12,637 …
necrosis factor (TNF)-α … clinical trials and post-marketing safety surveillance in 12,637 …
[HTML][HTML] Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
F Fa'ak, M Buni, A Falohun, H Lu, J Song… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
… results from a retrospective, multicenter study that evaluated … be answered only in a clinical
trial setting. Our data have also … how we can effectively decouple autoimmunity from antitumor …
trial setting. Our data have also … how we can effectively decouple autoimmunity from antitumor …
Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis
SH Hsu, TF Tsai - Expert Review of Clinical Pharmacology, 2020 - Taylor & Francis
… Alefacept, efalizumab, anti-tumor necrosis factors, anti-… be the exact target of ustekinumab
in psoriasis. Also, due to … patients with a history or current infection of hepatitis B or C. …
in psoriasis. Also, due to … patients with a history or current infection of hepatitis B or C. …
[HTML][HTML] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of …, 2020 - Elsevier
… Recently, a multicenter study was conducted evaluating the … and hepatitis B/C is advocated
and mandatory in high-risk … If failure occurs, we propose ustekinumab, tofacitinib, or …
and mandatory in high-risk … If failure occurs, we propose ustekinumab, tofacitinib, or …
Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review
Y Wang, P Zhang, Y Lv, Y Deng, M Yao… - Clinical, Cosmetic …, 2023 - Taylor & Francis
… treat psoriasis with comorbid chronic hepatitis B. Citation38 … of using ustekinumab for the
treatment of psoriasis comorbid with … Based on this observation, a retrospective cohort study …
treatment of psoriasis comorbid with … Based on this observation, a retrospective cohort study …
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients
M Megna, E Camela, T Battista, L Genco… - … on Drug Safety, 2023 - Taylor & Francis
… patients in a multicenter retrospective study involving 356 … a retrospective observational
study involving 27 psoriatic … ± 0.9 at week 52 in patients receiving ustekinumab and to 2.0 ± 0.6 …
study involving 27 psoriatic … ± 0.9 at week 52 in patients receiving ustekinumab and to 2.0 ± 0.6 …